Intraocular Pressure

Biomarker

Related News

Gene and optogenetic therapies in retinitis pigmentosa show mixed early and long-term results

May 12, 2026

Recent studies in retinitis pigmentosa showed mixed results for gene and optogenetic therapies. UGX-201 and MCO-010 were associated with visual acuity improvements, while AAV8.hPDE6A showed no significant functional gains at 1 year.

Nicox Receives Positive FDA Feedback for NCX 470 Glaucoma Treatment Ahead of NDA Submission

Feb 16, 2026

Nicox SA received positive written feedback from a pre-NDA meeting with the FDA for NCX 470, a nitric oxide-donating bimatoprost eye drop for glaucoma. The NDA submission remains on track for summer 2026.